- Frequent shedding of multi-drug resistant pneumococci among adults living with 1
- 2 HIV on suppressive antiretroviral therapy in Malawi
- Lusako Sibale^{1,2†}, Joseph Phiri^{1,2†}, Ndaona Mitole¹, Newton Kalata¹, Tinashe Nyazika², 4
- Alice Kalirani¹, Mercy Khwiya¹, Gift Sagawa¹, Deus Thindwa¹, Todd D Swarthout³, Neil 5
- French⁴, Ken Malisita⁵, Arox Kamng'ona⁶, Daniela M Ferreira^{2,7}, Robert S. Heyderman³, 6
- Brenda A. Kwambana-Adams^{1,2,3}, Kondwani Jambo^{1,2*}. 7
- 1. Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi 9
- 10 2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,
- UK 11

8

- 12 3. NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection
- and Immunity, University College London, WC1E 6JF, London, UK 13
- 4. Institute of Infection Veterinary & Ecological Science, University of Liverpool, L69 14
- 3GE, Liverpool, UK 15
- 5. Lighthouse-Queens Elizabeth Hospital and Gateway Health Centre, Blantyre, 16
- 17 Malawi

21

24

- 6. School of Life Science and Allied Health Professions, Kamuzu University of Health 18
- 19 Sciences, Blantyre, Malawi
- 20 7. Oxford Vaccine Group, University of Oxford, Oxford, UK
- *Corresponding author 22
- Email: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw (KCJ) 23
- 25 + Contributed equally to this manuscript
- 27 Running title: PLHIV shed multi-drug resistant pneumococci
- 28 Keywords: HIV, ART, Streptococcus pneumoniae, carriage, AMR
- 29 WOF Charge that 3735 new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract People living with human immunodeficiency virus (PLHIV) on antiretroviral therapy (ART) are reported to have three times higher carriage of *Streptococcus pneumoniae* than their HIV-uninfected counterparts in point prevalence studies. Using a longitudinal cohort study design, we assessed pneumococcal carriage density, shedding and antibiotic resistance profiles, as well as nasal mucosal immunity, in otherwise healthy PLHIV on ART for at least one year, compared to HIV-uninfected participants in Malawi. Pneumococcal carriage density was higher among PLHIV compared to HIV-uninfected participants. Moreover, PLHIV were twice more likely to shed pneumococci than HIV-uninfected participants. In PLHIV, aerosol shed pneumococci were more often multi-drug resistant (MDR) than nasopharyngeal carried isolates recovered from the same individual. Consistent with high shedding, PLHIV exhibited heightened neutrophil-mediated nasal mucosa inflammation. We propose that PLHIV should be considered in intervention strategies, such as vaccination, as they could be an important reservoir for transmission of MDR S. pneumoniae. Word count: 149 words

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Introduction Streptococcus pneumoniae has at least 100 distinct serotypes ^{1, 2} and is a common coloniser of the human nasopharynx. Pneumococcal carriage is a prerequisite for lifethreatening invasive pneumococcal disease (IPD) including pneumonia, meningitis, and bacteraemia ³, and is critical for transmission ⁴. In high- and middle-income countries, infant pneumococcal conjugate vaccine (PCV) programmes have resulted in a significant reduction in pneumococcal carriage and IPD in both vaccinated children (direct protection) and unvaccinated older children and adults (indirect protection) ^{5, 6, 7, 8}. However, in low-income countries such as Malawi, where the 13valent PCV (PCV13) was introduced into the infant immunisation programme in 2011, there is limited indirect protection among unvaccinated older children and adults despite evidence of substantial direct protection against IPD among vaccinated children ⁹. Moreover, pneumococcal carriage prevalence has been reported to be over two-fold higher in PLHIV on antiretroviral therapy (ART) (40-60%) than in those HIVuninfected (8-15%) or ART-naïve PLHIV (18-25%) ^{10, 11}. Residual carriage of all PCV13 serotypes (VTs) among Malawian adults living with HIV on ART has remained relatively high ^{7, 11}, with low socioeconomic status having been shown to exacerbate overall carriage prevalence¹². Emergence of pneumococcal antimicrobial resistance (AMR) is associated with carriage and antibiotic usage ^{13, 14, 15}. *S. pneumoniae* is among the priority bacterial pathogens due to its increased resistance to penicillin according to World Health Organisation (WHO) Global Antimicrobial Resistance and Use Surveillance System (GLASS) ¹⁶. It has been shown that PLHIV are more likely to take antibiotics, including cotrimoxazole prophylaxis to prevent opportunistic bacterial infections^{17, 18}. Moreover, PLHIV are also at increased risk of disease caused by respiratory viruses compared to the general population^{19, 20}. Common viral co-infections ^{21, 22, 23},

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

including Respiratory Syncytial Virus (RSV) and Influenza ²⁴, have been shown to promote high pneumococcal carriage density that in turn drives increased bacterial shedding ^{21, 25, 26}, a surrogate for transmission potential ^{27, 28}. Furthermore, high pneumococcal carriage density has been shown to associate with invasive pneumococcal disease ^{29, 30}. Together, this may suggest that in addition to being at increased risk of invasive pneumococcal disease, PLHIV could be an underappreciated reservoir driving transmission of antimicrobial resistant pneumococci in the community, calling for an in-depth evaluation of this population. Using a longitudinal cohort study, we investigated pneumococcal carriage density and shedding, as well as nasal immunity, in otherwise healthy PLHIV on ART for more than one year and HIV-uninfected participants. We show that PLHIV exhibit higher density pneumococcal carriage and more commonly shed antimicrobial resistant pneumococci. These findings have broader implications in the development of interventions to curb AMR pneumococcal disease and transmission. **Results** Clinical and demographic characteristics Between July 2019 and August 2021, we screened 512 adults among whom 28% (144/512) had confirmed pneumococcal carriage and thus eligible for recruitment (Fig. 1). Of these, 37.5% (54/144) were HIV-uninfected and 62.5% (90/144) were PLHIV on ART for more than 1 year (median 5.5 years [IQR 2.8-10.1]) (Table S1). Due to Coronavirus disease (COVID-19) pandemic restrictions, 37.5% (54/144) did not complete the study follow-up period of 5 months (Fig. 1). Therefore, the final analysis is restricted to the 35 HIV-uninfected participants and 55 PLHIV that completed the 5 months follow-up period. PLHIV, compared to HIV-uninfected participants were older, with 44% (24/55) and 20% (7/35) > 36 years old, respectively (p=0.049). Likewise, compared to HIV-uninfected participants, PLHIV had a lower socioeconomic status as measured by asset ownership index ¹² (median 4 [IQR 2.0-5.0] vs. 6 [3.5-

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

7.50], p=0.005), and a lower CD4 count (median 514 cells/µl [IQR 652-927] vs. 760 cells/µl [IQR [332-750], p<0.001) (Table 1). Higher NVT carriage positivity in PLHIV than HIV-uninfected participants Overall (VT + non-VT [NVT]) pernasal swab pneumococcal positivity was higher among PLHIV compared to HIV-uninfected participants (72% [95% CI 68.2–76.2] vs. 59% [53.7–64.8] p<0.001) (Fig. 2a). Furthermore, NVT pernasal swab pneumococcal positivity was higher in PLHIV (55.5% [51.2–59.7] vs. 44.9% [39.6–50.2], p=0.002) (Fig. 2b). In contrast, VT pernasal swab pneumococcal positivity was similar between PLHIV and HIV-uninfected participants: 19.6% [16.4–23.2] and 18.6% [14.6-23.0], p=0.5777 (Fig. 2a). The dominant VT carriage isolates among both PLHIV, and HIVuninfected participants were serotype 3 (49.1% and 43.1%) and serotype 19F (19.4%) and 29.2%) respectively (Fig. 2c). Using a multivariable logistic regression model (adjusting for age, gender, season, socioeconomic status and HIV status), showed that PLHIV were more likely to carry NVT than HIV-uninfected participants (adjusted odds ratio (aOR) 1.4, (95% CI 1.1-1.9, p=0.015)) (Table S2a). In contrast, the likelihood of having VT carriage was similar between PLHIV and HIV-uninfected participants (aOR 1.0, (95% CI 0.7-1.5, p>0.9) (Table S2b). Together, these data show that high pneumococcal carriage prevalence in PLHIV is mostly driven by NVT, but also highlight high residual VT carriage of serotype 3 and 19F in both PLHIV and HIVuninfected participants. Higher density pneumococcal carriage in PLHIV than HIV-uninfected participants The overall median pneumococcal carriage density was higher among PLHIV (40,738.03CFU/ml [95% CI 16218.1-104712.9] vs. 10,000.00CFU/ml [4466.84-22908.68], p<0.001) (Fig. 3). In a multivariable logistic regression model (adjusting for sex, age, carriage density, season, and socioeconomic status), PLHIV were more likely to harbour higher density carriage than HIV-uninfected participants (aOR 1.6, 1.1-2.5,

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

p=0.027) (Table 2). Collectively, these findings show high propensity for high-density carriage in PLHIV. Higher proportion of pneumococcal shedding in PLHIV than HIV-uninfected participants Considering the high-density carriage in PLHIV, we sought to determine whether they were also more likely to shed pneumococci than HIV-uninfected participants. The overall proportion of adults shedding pneumococci using either sampling technique was significantly higher among PLHIV than HIV-uninfected participants (57.6% [95% CI 48.4-66.4] vs. 27.3% [18.3-45.4], p<0.001) (Fig. 3a). Further analysis revealed that NVT were shed more frequently in PLHIV than HIV-uninfected participants (31.6% [25.9-37.8] vs. 11.2% [5.7-19.2], p<0.001) (Fig. 3b). However, VT shedding was similar between PLHIV on ART and HIV-uninfected participants (6% [3.4-9.7] vs. 5.1% [1.7-11.5], p=0.946) (Fig. 3b). Among the shed VT isolates, serotype 3 (73.3% and 40%) and serotype 19F (13.3% and 60%) were dominant among both the PLHIV and HIV-uninfected participants, respectively (Fig. 3c). Moreover, the overall proportion of adults shedding pneumococci were significantly higher in both the mechanical (40.3% [95% CI 31.6-49.5] vs. 18.4% [8.8-32], p=0.010) and aerosol (36% [95% CI 27.6-45.1] vs. 14.3% [95% CI 5.9-27.2], p=0.009) samples in PLHIV than HIV-uninfected participants (Fig 3d-e). To identify factors influencing pneumococcal shedding, we performed a multivariable logistic regression analysis that included age, gender, socioeconomic status, season, pneumococcal carriage density, and HIV status. HIV status and pneumococcal carriage density were significantly associated with pneumococcal shedding (Table 3). Specifically, PLHIV were twice more likely to shed any pneumococci than HIVuninfected participants (aOR 2.4, 95% CI 1.04-5.7, p=0.039), while individuals with high-density pneumococcal carriage, irrespective of HIV status, were greater than three times more likely to shed any pneumococci than those with low-density

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

carriage (aOR 3.37, 1.56-7.29, p=0.002) (Table 3). Together, these findings show that high proclivity for pneumococcal shedding in PLHIV, and in individuals with high density carriage (irrespective of HIV status). PLHIV shed antimicrobial resistant pneumococci Next, we sought to assess the antimicrobial susceptibility profile of the carried and shed isolates from PLHIV and HIV-uninfected participants. Overall, the antimicrobial susceptibility profile of nasopharyngeal carriage isolates was similar between PLHIV compared and HIV-uninfected participants (Table 5). However, the proportion of cotrimoxazole resistant isolates was significantly higher in PLHIV (98% [95% CI 88%-100%] vs. 76% [58%-89%], p=0.002) (Table 4). The overall proportion of nonsusceptible tetracycline (Tet), benzylpenicillin (PenG), as well as multi-drug resistant isolates were significantly higher in aerosol shed isolates compared to nasopharyngeal carriage isolates in PLHIV for samples collected from the same individual (Tet, 61% [95% CI 46%-75%] vs. 26% [14%-41%], p<0.001; PenG, 61% [46%-75%] vs. 32% [19%-48%], p=0.010; MDR, 64% [48%-77%] vs. 30% [CI 17%-45%], p=0.001) (Table 5). In contrast, the AMR profile of mechanical shed isolates were similar to the nasopharyngeal carriage isolates (Table 6). Among HIV-uninfected participants, no differences were observed in the antimicrobial susceptibility profile between shed and carriage isolates, irrespective of the shedding route (Table S3). Together, these data show that PLHIV shed multi-drug resistant pneumococci, especially via the aerosol route. PLHIV exhibit neutrophil-mediated inflammation in the nasal mucosa Lastly, we sought to determine whether PLHIV have a more inflamed nasal mucosa than HIV-uninfected adults, as inflammation has been shown to play a significant role in pneumococcal shedding ^{31, 32, 33}. To do this, we recruited PLHIV on ART for more than 1 year, and age- and gender-matched HIV-uninfected adult controls, irrespective of pneumococcal carriage status, from whom nasal cells and nasal lining

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

fluid samples were collected weekly for 5 weeks (Fig. S1). Using flow cytometrybased immunophenotyping, we characterised the immune cell composition in the nasal mucosa, a representative gating strategy is shown in Fig 5a. The abundance of CD14⁺ monocytes (median ratio 0.01 [95% CI 0.001-0.011] vs 0.01 [95% CI 0-0.014], p=0.55) and CD3⁺ T cells (median ratio 0.04 [95% CI 0.01-0.07] vs 0.05 [95% CI 0.02-0.08], p=0.66) was similar between the two study groups (Fig 5b-c). In contrast, the abundance of neutrophils (median ratio 0.30 [95% CI 0.17-0.43] vs. 0.17 [95% CI 0.06-0.28], p=0.018) was higher in PLHIV than HIV-uninfected participants (Fig 5d). To get further understanding of the phenotype of neutrophils, we measured the expression of CD62L, which is down regulated during neutrophil activation ^{34, 35}. Neutrophils from PLHIV had lower expression of CD62L than those from HIVuninfected participants (Median fluorescent intensity (MFI) 310 [95% CI 264-356] vs. 399 [95% CI 345-453], p=0.017) (Fig 5e). Furthermore, PLHIV had higher concentrations of neutrophil pro-inflammatory markers in their nasal lining fluid including neutrophil extracellular traps (NETs) (3.9 ng/ml [95% CI 0-31.7] vs 1.2 ng/ml [95% CI 0-2.76], p=0.042) and myeloperoxidase (MPO) (393500 pg/ml [95% CI 311066-475934] vs 43425 pg/ml [95% CI 2008-84842], p=0.066), compared to HIVuninfected participants (Fig 5f-g). Together, these findings show heightened inflammation in the nasal mucosa of PLHIV. Discussion We assessed pneumococcal carriage dynamics in otherwise healthy PLHIV on ART for more than 1 year compared to HIV-uninfected adults. We found that PLHIV had high-density pneumococcal carriage and shed antimicrobial resistant *S. pneumoniae*. Moreover, PLHIV exhibited heightened neutrophil-associated inflammation in the nasal mucosa. These data highlight this vulnerable HIV-affected population as a potentially important reservoir for transmission of antimicrobial resistant pneumococci.

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

It is postulated that pneumococcal transmission is primarily through respiratory droplets ³⁶ but direct contact through hands as a vehicle has also been implicated ²⁷, ²⁸. Consistent with this, we observed pneumococcal shedding in adults through nose poking and coughing. Unlike isolates obtained from the nose poking samples (nasopharyngeal niche), aerosol shed *S. pneumoniae* (likely from the oropharyngeal niche) from PLHIV were more frequently penicillin-resistant and multidrug-resistant. Streptococcus mitis and Streptococcus oralis, commensals of the human oropharynx, have been implicated as a potential source of antibiotic resistance genes for S. pneumoniae ^{37, 38, 39, 40}, through horizontal gene transfer (HGT) of penicillin-binding protein (pbp) genes that drive emergence of β -lactam resistance ^{41, 42}. An analysis of publicly available pneumococcal genomes has highlighted that *S. mitis* as a more frequent donor of genetically diverse pbp gene fragments to S. pneumoniae compared with S. oralis, with horizontal acquisition mostly confined to pneumococcal serotypes associated with prolonged nasopharyngeal carriage duration ⁴⁰. These findings suggest that proximity between *S. pneumoniae* and other closely-related streptococci species harboring antibiotic resistance genes facilitates their transfer to pneumococci, and this could in part explain the predominance of penicillin-resistant pneumococci in the aerosol shed isolates. On the other hand, it has been recently shown that there is an elevated risk of both the acquisition and persistent carriage of multi-drug resistant pneumococci following antimicrobial treatment ⁴³. The mechanism of persistence of multi-drug resistant pneumococci was attributed to reduced within-host competition following antimicrobial treatment, indicating that in the absence of treatment, susceptible lineages outcompete resistant lineages ⁴³. In Malawi, as part of standard HIV clinical management, PLHIV are put on daily co-trimoxazole prophylaxis ^{17, 18}. Consistent with purifying selection and in agreement with previous studies 44,45, there was higher prevalence of co-trimoxazole resistant carriage isolates in PLHIV than HIV-

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

uninfected participants. Considering that co-trimoxazole is a broad-spectrum antimicrobial and its resistance is associated with penicillin resistance^{45, 46}, it could differentially alter the microbiota in the oropharyngeal and nasopharyngeal compartments, resulting in stronger selection for multi-drug resistant pneumococci. Consistent with their increased propensity for pneumococcal shedding, PLHIV exhibited neutrophil-driven nasal inflammation. Neutrophil factors including NETs and MPO contribute to clearance of pneumococcal infection ^{47, 48}, but also promote excessive inflammation ^{25, 49}. Host inflammation has been shown to drive pneumococcal shedding ^{31, 32, 33 50}. In mice models, pneumococcal virulence factors, such as pneumolysin and pneumococcal surface protein K (PspK), induce upper respiratory tract (URT) inflammation resulting in pneumococcal shedding ^{32, 33, 51}. Furthermore, uncontrolled inflammation has been shown to promote pneumococcal persistence via nutrient provision arising from increased mucus secretion ⁵² ^{53, 54}, and through reduced mucocilliary clearance of pneumococci due to altered ciliary beating 55. Together, this suggests that uncontrolled nasal inflammation in PLHIV, likely due to impaired nasal immunity ^{10, 56} or driven by altered URT microbiota, perpetuates nasal inflammation leading to increased pneumococcal shedding, a surrogate of transmission potential. Despite the strengths of this study, including a comprehensive assessment of carriage dynamics in a relevant population and setting, there are important limitations. First, the standard microbiological assay used in this study were biased towards isolating single isolates following culture, hence missing any potential multiple serotype carriage episodes or pneumococci carried at low densities. Second, we did not directly measure pneumococcal transmission. Although pneumococcal shedding is regarded as a surrogate for transmission potential ^{27, 28}, it is not clear how often shed pneumococci result in successful transmission. However, this does not discount our suggestion that PLHIV on ART for more than 1 year contribute to

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

transmission of multi-drug resistant pneumococci, which is of public health importance. In conclusion, our study demonstrates that PLHIV on ART for more than 1 year could be an important reservoir for transmission of multi-drug resistant *S. pneumoniae*. This has potential to derail the success of the infant PCV programme and our fight against antimicrobial resistance in high HIV prevalence and high pneumococcal carriage settings such as Malawi, especially now that there is an HIV test and treat strategy ⁵⁷. Considering that PCV was shown to be efficacious against recurrent IPD among PLHIV in Malawi⁵⁸, consideration should be given to re-evaluating the provision of pneumococcal vaccination to this vulnerable adult population. Methods Study design and recruitment We recruited asymptomatic PLHIV on ART for more than 1 year and HIV-uninfected adults in Blantyre, Malawi. Participants were recruited on day 3 after screening and then followed up on day 7, 14, 21 and 28 for the first month, and then every month for 5 months. All participants were recruited from the ART clinics and Voluntary Counselling and Testing (VCT) centres at Lighthouse-Queen Elizabeth Central Hospital and Gateway Health Centre in Blantyre. Briefly, participants were screened for pneumococcal carriage, using WHO recommendations for nasopharyngeal sampling and microbiological culture for pneumococcal detection ⁵⁹. Inclusion criteria included confirmed pneumococcal carriage, in adults aged 18 to 45 years, living with a child aged under-5-years and providing written informed consent. Exclusion criteria included receiving antibiotics in the previous 4 weeks (apart from co-trimoxazole prophylaxis as all PLHIV on ART receive daily co-trimoxazole prophylaxis as per national guidelines ¹⁷), hospitalization for pneumonia in the previous 4 weeks, having respiratory tract Kaposi's sarcoma or a terminal illness (e.g., metastatic malignancy, terminal AIDS). All PLHIV were on standardised ART regimen

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

according to Malawi Ministry of Health 2018 Clinical Management of HIV guidelines The study was conducted in accordance with good clinical practice (GCP) guidelines and the Declaration of Helsinki. Ethical approval was obtained from the College of Medicine Research Ethics Committee (COMREC) (P.11/18/2532) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTMREC) (19-033). Sample collection Nasopharyngeal swabs were collected at all time points, and a peripheral blood sample was collected at recruitment (day 3) from PLHIV on ART for measuring CD4 count. In addition, respiratory secretions were collected at day 3, 21, and 28, using a modified polyvinyl acetate (PVA) facemask device ^{61, 62, 63}, direct coughing onto an agar plate (coughing), and inserting the participants clean index finger into the front of the nose (nose poking). Further details of these methods are discussed in the supplementary section. Nasal cells were collected weekly (5 visits) by scraping the inferior turbinate using nasal curette (Rhino-probe, Arlington Scientific, UK) as previously described ⁶⁴. Per individual and timepoint, two curettes were collected from each nostril. Briefly, the four curette samples were immediately placed in a 15-ml falcon tube (Corning) containing 8-ml of precooled transport media (RPMI-1640 [Thermo Fisher Scientific Inc.) supplemented with 10% Fetal Bovine Saline [FBS], antibiotic/antimycotic [Sigma, USA], L-glutamine, non-essential amino acids, HERPES buffer and sodium pyruvate (all from Gibco, USA)). Nasal-lining fluid was collected weekly (5 visits) using a non-invasive method that uses a synthetic absorptive matrix (SAM) strip (Hunts Development Ltd, UK). Briefly, the nasosorption strip was advanced up the lumen of the nasal cavity and held inside

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

the nostril for up to three minutes until soaked. The strip was then removed and placed in a microcentrifuge tube for storage at -80°C until processing. Microbiological culture and density quantification Standard microbiologic culture was used to determine the presence of *S.* pneumoniae from the nasal swab, nose poke swab, cough onto an agar plate and modified PVA facemask^{61, 62, 63}. For modified PVA facemask processing, four PVA strips were removed from the mask using sterile technique and then dissolved in 10ml Todd Hewitt broth with 5% yeast (THY) and then plated. We identified S. pneumoniae by their morphology and optochin sensitivity on a gentamicin-sheep blood agar plate (SBG; 5% sheep blood agar, 5µL gentamicin/mL) after an overnight incubation at 37 °C in 5% CO₂. The bile solubility test was used on isolates with no or intermediate (zone diameter < 14mm) optochin susceptibility. Plates showing no S. pneumoniae growth were incubated for a further 24 hours before being reported as negative. A single colony of confirmed pneumococcus was selected and grown on a new SBG plate as before. Growth from this second plate was used for serotyping by latex agglutination (ImmuLexTM 23-valent Pneumotest; Statens Serum Institute, Denmark). This kit allows for differential identification of each PCV13 vaccine serotypes (VT) but not for differential identification of PCV13 non-vaccine serotypes (NVT); NVT and non-typeable isolates were, therefore, reported as NVT. Pneumococcal density was quantified using microbiological culture serial dilutions 65 on a gentamicin-sheep blood agar plate (SBG; 5% sheep blood agar, 5µL gentamicin/mL) and results reported as colony forming units per millilitre (CFU/ml). AMR profiling Pure pneumococcal isolates were cultured on sheep blood agar without antibiotics (SBA), using an overnight incubation at 37 °C in 5% CO₂. Growth from the SBA were emulsified in normal saline to match 0.5 McFarland turbidity standard and plated on

sheep blood Muller Hinton agar plate without antibiotics (MHB) using a sterile cotton

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

swab. The antimicrobial susceptibility of pneumococcal isolates was assessed by the disk diffusion method (Oxoid, USA) for beta lactams antibiotic (oxacillin 1µg), macrolide-lincosamide-streptogramin (MLS) antibiotic (erythromycin 15μg), tetracycline antibiotic (tetracycline 30µg) and Trimethoprim/sulfamethoxazole (cotrimoxazole 1.25–23.75μg). Beta lactams antibiotic susceptibility was confirmed by benzylpenicillin E-test minimum inhibitory concentration (MIC). E-test MICs were determined by suspending colonies from an overnight culture (incubation at 37 °C in 5% CO2) on SBA in saline, and the organism density was matched to a 0.5 McFarland turbidity standard. Using a sterile cotton swab, the organism suspension was plated onto MHB. E-test strips were applied to the surface of the plates according to the manufacturer's recommendations. Agar plates were incubated overnight at 37 °C in 5% CO2. The MIC was defined as the lowest concentration of drug where the zone edge intersected the E-test strip. Interpretation of results followed European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines ⁶⁶. Streptococcus pneumoniae ATCC 49619 was used as quality control. Multidrug resistance (MDR) was defined as nonsusceptibility to agents in three or more above chemical classes of antibiotic. Flow cytometry analysis For immunophenotyping, nasal cells were dislodged from curettes by repeated pipetting and stained with far-red fluorescent amine reactive dye (34973A, 1:1000) from Invitrogen, and incubated for 15 minutes followed by the addition of a cocktail of BV605 anti-human CD326 (9C4, 324224, 1:50), PerCp-Cy5.5 anti-human CD45 (HI30, 304028, 1:40), FITC anti-human CD66b (G10F5, 305104, 1:40), PE-Cy7 antihuman CD14 (M5E2, 301814, 1:40), APC-Cy7 anti-human CD3 (SK7, 344818, 1:40) and PE-eFlour® 610 anti-human CD62L (DREG-56, 61062942, 1:40), all from Bio legend

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

(UK). Samples were acquired on LSR FORTESSA flow cytometer equipped with FACSDIVA version 8.0.1 (BD Biosciences, UK) and analysed using Flowjo Version 10.8.1 (BD Biosciences, USA). Abundance of immune cells was normalised as immune cell to epithelial cell ratio as previously reported ⁶⁷. All flow cytometry data are available. Neutrophil-extracellular traps (NETs) enzyme linked-immunosorbent assay Nasosorption samples were eluted from stored nasosorption filters (Mucosal Diagnostics, Hunt Development (UK) Ltd, Midhurst, UK) using 200µL of elution buffer (Millipore) by centrifugation at 1500g for 10 minutes as previously described ⁶⁸. The eluate was cleared by further centrifugation at 1595g for 10 minutes. The eluate was then stored at -80°C until the day of the assay. The detection of NETs was performed by combining two commercial ELISA kits; ROCHE cell death ELISA kit (Sigma Aldrich, 11920685001) and Human Elastase ELISA Kit (Hycult®Biotech, HK319). In-house developed PMA NETs were serially diluted (1:2) and used as standards, while nasosorption samples were diluted (1:4) using 1X dilution buffer from the Elastase ELISA Kit (Hycult®Biotech, HK319). Myeloperoxidase (MPO) enzyme linked-immunosorbent assay Myeloperoxidase (MPO) enzyme linked immunosorbent assay was performed on eluted -80°C frozen nasal lining fluid samples as described in the manufacturer's user guide (Invitrogen, UK, BMS2038INST). Statistical analysis Descriptive statistics are reported as numbers and proportions for categorical variables, and median and confidence interval for continuous data. Categorical variables were compared using χ^2 test, and continuous variables were compared using Mann-Whitney test. We fitted a univariate and multivariable regression model, accounting for multiple sampling (generalized linear mixed model), covariables used

- 435 for each model are detailed in the supplementary section. All data analyses were
- 436 done in RStudio (Version 4.1.3, R Development Core Team, Vienna, Austria). Figures
- 437 and tables were produced in R (v4.1.3), RStudio (v2022.02. 2+485.pro2 Prairie Trillium
- April 27, 2022), ggplot2 (v3.3.5), lme4 (v1.1-28), and gtsummary (v1.5.2)⁶⁹. 438
- Statistical significance level was reported at a p value of <0.05. 439

441 Data availability

All data supporting these findings are available upon reasonable request. 442

References

- 446 Ganaie, F. et al. A new pneumococcal capsule type, 10D, is the 100th serotype
- and has a large cps fragment from an oral streptococcus. MBio 11, e00937-00920 447
- 448 (2020).

440

443

- 449 2. Ganaie, F. et al. Structural, genetic, and serological elucidation of
- Streptococcus pneumoniae serogroup 24 serotypes: Discovery of a new serotype, 450
- 24C, with a variable capsule structure. Journal of Clinical Microbiology, JCM. 00540-451
- 452 00521 (2021).
- 453 O'Brien, K.L. et al. Burden of disease caused by Streptococcus pneumoniae in
- children younger than 5 years: global estimates. The Lancet 374, 893-902 (2009). 454
- 455 4. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae:
- 456 transmission, colonization and invasion. Nat Rev Microbiol 16, 355-367 (2018).
- Waight, P.A. et al. Effect of the 13-valent pneumococcal conjugate vaccine on 457
- 458 invasive pneumococcal disease in England and Wales 4 years after its introduction:
- an observational cohort study. The Lancet Infectious Diseases 15, 535-543 (2015). 459
- 460 Moore, M.R. et al. Effect of use of 13-valent pneumococcal conjugate vaccine
- in children on invasive pneumococcal disease in children and adults in the USA: 461
- analysis of multisite, population-based surveillance. The Lancet Infectious Diseases 462
- 463 **15**, 301-309 (2015).
- Swarthout, T.D. et al. High residual carriage of vaccine-serotype Streptococcus 464
- pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nature 465
- Communications 11 (2020). 466
- Usuf, E. et al. Pneumococcal carriage in rural Gambia prior to the introduction 467
- 468 of pneumococcal conjugate vaccine: a population-based survey. Trop Med Int Health
- 20, 871-879 (2015). 469
- Bar-Zeev, N. et al. Impact and effectiveness of 13-valent pneumococcal 470
- conjugate vaccine on population incidence of vaccine and non-vaccine serotype 471
- invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective 472

- observational time-series and case-control studies. *The Lancet Global Health* **9**, e989-
- 474 e998 (2021).
- 475 10. Glennie, S.J. et al. Defective Pneumococcal-Specific Th1 Responses in HIV-
- 476 Infected Adults Precedes a Loss of Control of Pneumococcal Colonization. *Clinical*
- 477 *Infectious Diseases* **56**, 291-299 (2013).
- 478 11. Heinsbroek, E. et al. Persisting high prevalence of pneumococcal carriage
- among HIV-infected adults receiving antiretroviral therapy in Malawi. AIDS 29, 1837-
- 480 1844 (2015).
- 481 12. Thindwa, D. et al. Risk factors for pneumococcal carriage in adults living with
- 482 HIV on antiretroviral therapy in the infant pneumococcal vaccine era in Malawi.
- 483 *medRxiv* (2022).
- 484 13. Lehtinen, S. et al. Evolution of antibiotic resistance is linked to any genetic
- 485 mechanism affecting bacterial duration of carriage. *Proceedings of the National*
- 486 Academy of Sciences 114, 1075-1080 (2017).
- 487 14. Tonkin-Hill, G. et al. Pneumococcal within-host diversity during colonisation,
- 488 transmission and treatment. Cold Spring Harbor Laboratory; 2022.
- 489 15. Chaguza, C. et al. Recombination in Streptococcus pneumoniae lineages
- 490 increase with carriage duration and size of the polysaccharide capsule. *MBio* **7**,
- 491 e01053-01016 (2016).
- 492 16. Organization, W.H. World Health Organization. Global antimicrobial resistance
- and use surveillance system (GLASS) report. (2021).
- 494 17. Organization, W.H. *Guidelines on post-exposure prophylaxis for HIV and the*
- 495 use of co-trimoxazole prophylaxis for HIV-related infections among adults,
- 496 adolescents and children: recommendations for a public health approach: December
- 497 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral
- 498 drugs for treating and preventing HIV infection. World Health Organization, 2014.
- 499 18. Laurens, M.B. et al. Revisiting Co-Trimoxazole Prophylaxis for African Adults in
- 500 The Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. *Clinical*
- 501 *Infectious Diseases* (2021).
- 502 19. Ho, A. et al. Epidemiology of Severe Acute Respiratory Illness and Risk Factors
- for Influenza Infection and Clinical Severity among Adults in Malawi, 2011–2013. *The*
- 504 American Journal of Tropical Medicine and Hygiene 99, 772-779 (2018).
- 505 20. Ho, A. et al. Impact of Human Immunodeficiency Virus on the Burden and
- 506 Severity of Influenza Illness in Malawian Adults: A Prospective Cohort and Parallel
- 507 Case-Control Study. *Clinical Infectious Diseases* **66**, 865-876 (2018).
- 508 21. Manna, S. et al. Synergism and Antagonism of Bacterial-Viral Coinfection in
- the Upper Respiratory Tract. *mSphere* **7**, e0098421 (2022).
- 510 22. Karppinen, S. et al. Acquisition and Transmission of Streptococcus
- 511 pneumoniae Are Facilitated during Rhinovirus Infection in Families with Children. Am
- 512 *J Respir Crit Care Med* **196**, 1172-1180 (2017).
- 513 23. Peterson, I. et al. Respiratory Virus–Associated Severe Acute Respiratory Illness
- and Viral Clustering in Malawian Children in a Setting With a High Prevalence of HIV

- Infection, Malaria, and Malnutrition. *Journal of Infectious Diseases* **214**, 1700-1711
- 516 (2016).
- 517 24. Zawłocka, E., Czajkowska, M., Wrotek, A. & Jackowska, T. P388 RSV and
- influenza co-infections in children in three consecutive influenza epidemic seasons.
- 519 Archives of Disease in Childhood **104**, A311 (2019).
- 520 25. Jochems, S.P. et al. Inflammation induced by influenza virus impairs human
- innate immune control of pneumococcus. *Nat Immunol* **19**, 1299-1308 (2018).
- 522 26. Murakami, D. et al. Exposure to Cigarette Smoke Enhances Pneumococcal
- 523 Transmission Among Littermates in an Infant Mouse Model. Front Cell Infect
- 524 *Microbiol* **11**, 651495 (2021).
- 525 27. Connor, V. et al. Hands are vehicles for transmission of Streptococcus
- 526 pneumoniae in novel controlled human infection study. *European Respiratory Journal*
- **52**7 **52**, 1800599 (2018).
- 528 28. Smith-Vaughan, H., Crichton, F., Beissbarth, J., Morris, P.S. & Leach, A.J.
- 529 Survival of pneumococcus on hands and fomites. *BMC Research Notes* 1, 112 (2008).
- 530 29. Wolter, N. et al. High Nasopharyngeal Pneumococcal Density, Increased by
- 531 Viral Coinfection, Is Associated With Invasive Pneumococcal Pneumonia. *The Journal*
- *of Infectious Diseases* **210**, 1649-1657 (2014).
- 533 30. Carr, O.J.J. et al. Nasopharyngeal Pneumococcal Colonization Density Is
- Associated With Severe Pneumonia in Young Children in the Lao People's
- 535 Democratic Republic. *The Journal of Infectious Diseases* **225**, 1266-1273 (2021).
- 536 31. Zangari, T., Ortigoza, M.B., Lokken-Toyli, K.L. & Weiser, J.N. Type I Interferon
- 537 Signaling Is a Common Factor Driving Streptococcus pneumoniae and Influenza A
- 538 Virus Shedding and Transmission. *mBio* **12** (2021).
- 539 32. Zafar, M.A. et al. Identification of Pneumococcal Factors Affecting
- 540 Pneumococcal Shedding Shows that the dlt Locus Promotes Inflammation and
- 541 Transmission. *mBio* **10** (2019).
- 33. Zafar, M.A., Wang, Y., Hamaguchi, S. & Weiser, J.N. Host-to-Host Transmission
- of Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell*
- 544 *Host Microbe* **21**, 73-83 (2017).
- 545 34. Ekstedt, S., Larsson, O., Kumlien Georén, S. & Cardell, L.O. CD16(high)
- 546 CD62L(dim) neutrophils induce nerve-mediated airway hyperreactivity. *Clin Exp*
- 547 *Allergy* **50**, 756-759 (2020).
- 548 35. Ivetic, A., Hoskins Green, H.L. & Hart, S.J. L-selectin: A Major Regulator of
- Leukocyte Adhesion, Migration and Signaling. Front Immunol 10, 1068 (2019).
- 550 36. Hodges, R.G. & Macleod, C.M. Epidemic Pneumeeoccal Pneumonia. II. The
- Influence of Population Characteristics and Environment. *American journal of hygiene*
- **44**, 193-206 (1946).
- 553 37. Hohwy, J., Reinholdt, J. & Kilian, M. Population dynamics of Streptococcus
- mitis in its natural habitat. *Infection and immunity* **69**, 6055-6063 (2001).
- 555 38. Jensen, A., Valdórsson, O., Frimodt-Møller, N., Hollingshead, S. & Kilian, M.
- 556 Commensal streptococci serve as a reservoir for β-lactam resistance genes in

- 557 Streptococcus pneumoniae. *Antimicrobial agents and chemotherapy* **59**, 3529-3540
- 558 (2015).
- 559 39. Ready, D., Bedi, R., Spratt, D., Mullany, P. & Wilson, M. Prevalence, proportions,
- and identities of antibiotic-resistant bacteria in the oral microflora of healthy
- 561 children. *Microbial Drug Resistance* **9**, 367-372 (2003).
- 562 40. Kalizang'oma, A. et al. Streptococcus pneumoniae serotypes that frequently
- colonise the human nasopharynx are common recipients of penicillin-binding protein
- gene fragments from Streptococcus mitis. *Microb Genom* **7** (2021).
- 565 41. Jensen, A., Valdórsson, O., Frimodt-Møller, N., Hollingshead, S. & Kilian, M.
- 566 Commensal streptococci serve as a reservoir for β-lactam resistance genes in
- 567 Streptococcus pneumoniae. *Antimicrob Agents Chemother* **59**, 3529-3540 (2015).
- 568 42. Sauerbier, J., Maurer, P., Rieger, M. & Hakenbeck, R. Streptococcus
- 569 pneumoniae R6 interspecies transformation: genetic analysis of penicillin resistance
- determinants and genome-wide recombination events. *Mol Microbiol* **86**, 692-706
- 571 (2012).
- 572 43. Tonkin-Hill, G. et al. Pneumococcal within-host diversity during colonization,
- transmission and treatment. *Nature Microbiology* (2022).
- 574 44. Pemba, L. et al. Impact of cotrimoxazole on non-susceptibility to antibiotics in
- 575 Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in
- 576 South Africa. *Journal of Infection* **56**, 171-178 (2008).
- 577 45. Seid, M. et al. Does cotrimoxazole prophylaxis in HIV patients increase the
- 578 drug resistance of pneumococci? A comparative cross-sectional study in southern
- 579 Ethiopia. *PLOS ONE* **15**, e0243054 (2020).
- 580 46. Liñares, J., Perez, J., Garau, J., Murgui, L. & Martin, R. Comparative
- 581 susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin,
- rifampicin and fourteen β-lactam antibiotics. *Journal of Antimicrobial Chemotherapy*
- **13**, 353-359 (1984).
- 584 47. Monteith, A.J., Miller, J.M., Maxwell, C.N., Chazin, W.J. & Skaar, E.P. Neutrophil
- extracellular traps enhance macrophage killing of bacterial pathogens. Sci Adv 7,
- 586 eabj2101 (2021).
- 587 48. Nikolaou, E. et al. Experimental Human Challenge Defines Distinct
- 588 Pneumococcal Kinetic Profiles and Mucosal Responses between Colonized and Non-
- 589 Colonized Adults. *mBio* **12** (2021).
- 590 49. Dong, Y. et al. TLR4 regulates ROS and autophagy to control neutrophil
- 591 extracellular traps formation against Streptococcus pneumoniae in acute otitis media.
- 592 *Pediatr Res* **89**, 785-794 (2021).
- 593 50. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae:
- transmission, colonization and invasion. *Nature Reviews Microbiology* **16**, 355-367
- 595 (2018).
- 596 51. Sakatani, H. et al. A Novel Pneumococcal Surface Protein K of
- 597 Nonencapsulated Streptococcus pneumoniae Promotes Transmission among
- 598 Littermates in an Infant Mouse Model with Influenza A Virus Coinfection. *Infect*
- 599 *Immun* **90**, e0062221 (2022).

- 600 52. Siegel, S.J., Roche, A.M. & Weiser, J.N. Influenza promotes pneumococcal
- 601 growth during coinfection by providing host sialylated substrates as a nutrient
- 602 source. *Cell Host Microbe* **16**, 55-67 (2014).
- 603 53. Hammond, A.J. et al. Neuraminidase B controls neuraminidase A-dependent
- mucus production and evasion. *PLoS Pathog* **17**, e1009158 (2021).
- 605 54. Wu, M. et al. Epithelium-derived IL17A Promotes Cigarette Smoke-induced
- Inflammation and Mucus Hyperproduction. *Am J Respir Cell Mol Biol* **65**, 581-592
- 607 (2021).
- 608 55. Sender, V., Hentrich, K. & Henriques-Normark, B. Virus-Induced Changes of
- 609 the Respiratory Tract Environment Promote Secondary Infections With Streptococcus
- pneumoniae. Front Cell Infect Microbiol 11, 643326 (2021).
- 56. Jambo, K.C. et al. Bronchoalveolar CD4+ T cell responses to respiratory
- antigens are impaired in HIV-infected adults. *Thorax* **66**, 375-382 (2011).
- 613 57. Ministry of Health and Population , M. Malawi Clinical HIV Guidelines. In:
- Ministry of Health and Population, M., editor.; 2018.
- 615 58. French, N. et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-
- 616 infected adults. *N Engl J Med* **362**, 812-822 (2010).
- 617 59. Satzke, C. et al. Standard method for detecting upper respiratory carriage of
- 618 Streptococcus pneumoniae: Updated recommendations from the World Health
- 619 Organization Pneumococcal Carriage Working Group. *Vaccine* **32**, 165-179 (2013).
- 620 60. Ministry of Health, M. Clinical management of HIV in Children and Adults;
- 621 2011.
- 622 61. Al-Taie, A. et al. 3-D printed polyvinyl alcohol matrix for detection of airborne
- pathogens in respiratory bacterial infections. *Microbiological research* **241**, 126587
- 624 (2020).
- 625 62. Williams, C.M. et al. Exhaled SARS-CoV-2 quantified by face-mask sampling in
- hospitalised patients with COVID-19. *Journal of Infection* **82**, 253-259 (2021).
- 627 63. Hu, B. Recent advances in facemask devices for in vivo sampling of human
- 628 exhaled breath aerosols and inhalable environmental exposures. *TrAC Trends in*
- 629 *Analytical Chemistry*, 116600 (2022).
- 630 64. Jochems, S.P. et al. Novel analysis of immune cells from nasal microbiopsy
- demonstrates reliable, reproducible data for immune populations, and superior
- 632 cytokine detection compared to nasal wash. *PloS one* **12**, e0169805 (2017).
- 633 65. Miles, A.A., Misra, S.S. & Irwin, J.O. The estimation of the bactericidal power of
- the blood. *Epidemiology and Infection* **38**, 732-749 (1938).
- 635 66. Testing, T.E.C.o.A.S. Breakpoint tables for interpretation of MICs and zone
- 636 diameters; 2022.
- 637 67. Roukens, A.H.E. et al. Prolonged activation of nasal immune cell populations
- and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses
- 639 following COVID-19. *Nature Immunology* **23**, 23-32 (2022).
- 640 68. Morton, B. et al. Distinct clinical and immunological profiles of patients with
- evidence of SARS-CoV-2 infection in sub-Saharan Africa. *Nat Commun* 12, 3554
- 642 (2021).

644

645 646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

69. Larmarange, D.D.S.a.K.W.a.M.C.a.J.A.L.a.J. Reproducible Summary Tables with the gtsummary Package. The R Journal 13, 570-580 (2021). **Acknowledgements** The authors thank all study participants, and the staff of the Queen Elizabeth Central Hospital (QECH) Lighthouse and Gateway Clinic, for their support and co-operation during the study. This work was supported by the National Institute for Health Research (NIHR) [16/136/46]. KCJ is supported by an MRC African Research Leader award [MR/T008822/1]. RSH is a NIHR senior investigator. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK government. A Wellcome Strategic award number 206545/Z/17/Z supports MLW. The funders were not involved in the design of the study; in the collection, analysis, and interpretation of the data; and in writing the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funders. **Author contributions** The author contributions were as follows: Methodology: K.C.J., R.S.H. and N.F. Investigation: L.S., J.P., N.M., N.K., T.N., A.K., M.K., and G.S. Data analysis: K.C.J., L.S., and J.P. Interpretation: K.C.J., L.S., J.P., R.S.H., B.K.A, T.D.S., and N.F. Data curation: L.S. and J.P. Project administration: N.M., N.K. and K.C.J. Sample collection: A.K., M.K., and G.S. Writing: L.S., J.P., and K.C.J. Conceptualisation and supervision: K.C.J., R.S.H., B.K.A, and N.F. All authors read and approved the final manuscript. Corresponding author Correspondence to Kondwani C. Jambo Competing interests The authors declare no competing interests

Figures

673

674 675 676


677

678

679 680

681

A.






Figure 1. Recruitment flow diagram and study design. A) Flow diagram showing the number of adults and pneumococcal samples included in the analysis among PLHIV on ART and HIV uninfected participants. B) Sampling strategy, showing longitudinal follow up of study participants and sample collection points.




Figure 2. Overall (VT+NVT) pneumococcal swab positivity among PLHIV and HIV-uninfected adults. A) HIV-stratified pneumococcal swab positivity. B) HIV and serogroup stratified pneumococcal swab positivity by different nasopharyngeal sampling visits. C) HIV and serogroup stratified pneumococcal swab positivity. D) HIV-stratified proportion of PCV13 serotypes. The denominator for each serotype is the total PCV13 serotypes in each group. Black vertical lines represent 95% confidence intervals. Data were analysed using Chi-square test (HIV-uninfected: n=35, PLHIV: n=55). Source data are provided as a Source Data file. PCV13, pneumococcal conjugated vaccine 13; ART, antiretroviral therapy; NVT non-PCV13 serotype; VT, PCV13 serotypes




Figure 3. Pneumococcal carriage density among PLHIV and HIV-uninfected participants. Log median carriage density stratified by HIV status for 5 months study follow-up time. For all boxplots, box boundaries correspond to 25th and 75th percentiles; whiskers extend to a maximum of 1.5x the inter-quartile range, with values outside the box and whiskers being outliers. Data were analysed using Wilcoxon test (HIV-uninfected: n=35, PLHIV: n=55). Source data are provided as a Source Data file. ART, antiretroviral therapy; CFU, colony forming units

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 4. Pneumococcal shedding among PLHIV and HIV-uninfected adults. Pneumococcal shedding was defined as presence of viable pneumococci following microbiological culture of samples collected through nose poking (mechanical) and coughing or facemask sampling (aerosol). A) Overall pneumococcal shedding positivity stratified by HIV status. B). Overall pneumococcal shedding positivity stratified by HIV status and serogroup. C). Overall pneumococcal shedding positivity stratified by HIV status and PCV13 serotypes, the denominator for each serotype is the total PCV13 serotypes in each group. D). Pneumococcal mechanical shedding positivity stratified by HIV status E). Pneumococcal aerosol shedding positivity stratified by HIV status. The vertical bars represent median and horizontal lines represent confidence intervals (CI) (black lines). Data were analysed using Chi-square test (HIV-uninfected: n=23, PLHIV: n=61). Source data are provided as a Source Data file. ART, antiretroviral therapy




Figure 5. Nasal immune responses in adults with or without HIV. Immune cell profiling was done on nasal curette-collected mucosa cells using flow cytometry-based immunophenotyping, while concentration of NETs and MPO were measured in nasal lining fluid using ELISAs, in HIV-uninfected adults and PLHIV. Samples were collected weekly for 4 weeks in all participants. A) Representative flow cytometry plot from an HIV-uninfected participant showing a gating strategy for the identification of immune cells in the nasal mucosa. B-D) Plots showing abundance of immune cell

subsets at all time points in the nasal mucosa of HIV-uninfected and PLHIV. Data was normalised as immune cell to epithelial cell ratio. E) Median fluorescence Intensity (MFI) of CD62L expression on neutrophils between HIV-uninfected and PLHIV at all time points. For all boxplots, box boundaries correspond to 25th and 75th percentiles; whiskers extend to a maximum of 1.5x the inter-quartile range, with values outside the box and whiskers being outliers. Data were analysed using Wilcoxon test (HIVuninfected: n=10, PLHIV: n=9). Source data are provided as a Source Data file. ART, antiretroviral therapy

Table 1

Table 1. Baseline characteristics						
Characteristic	HIV- , N = 35 ¹	PLHIV , N = 55 ¹	p-value			
Sex			0.7			
Female	25 (71%)	41 (75%)				
Male	10 (29%)	14 (25%)				
Age group			0.049			
18-25	12 (34%)	10 (18%)				
26-35	16 (46%)	21 (38%)				
36-45	7 (20%)	24 (44%)				
Number of U5 children per household			0.7			
1	26 (74%)	45 (82%)				
2	8 (23%)	9 (16%)				
3	1 (2.9%)	1 (1.8%)				
Socioeconomic status ³			0.005			
Median (IQR)	6.00 (3.50, 7.50)	4.00 (2.00, 5.00)				
CD4 count (Cells/µI)			<0.001			
Median (IQR)	760 (652, 927)	514 (332, 750)				
ART duration (Years)						
Median (IQR)	NA (NA, NA)	5.8 (3.4, 11.3)				
HIV viral load (Copies/ml) ⁴						
Median (IQR)	NA (NA, NA)	39 (39, 18,928)				
1 - (0/)						

¹ n (%)

² Pearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test

³ Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television

⁴ i.e. Only 10 PLHIV on ART>1yr had a detectable Viral load

Table 2. Pneumococcal density <=2010CFU/ml vs Pneumococcal density >2010CFU/ml

		Univariate			Multivariable		
Characteristic	OR ¹	95% CI ¹	p-value	OR ¹	95% CI ¹	p-value	
HIV status							
HIV-	_	_		_	_		
PLHIV	1.55	1.04, 2.31	0.030	1.62	1.06, 2.49	0.027	
Sex							
Female	_	_		_	_		
Male	0.92	0.59, 1.43	0.7	0.85	0.53, 1.36	0.5	
Age group							
18-25	_	_		_	_		
26-35	0.84	0.50, 1.40	0.5	0.69	0.40, 1.20	0.2	
36-45	0.94	0.56, 1.59	0.8	0.69	0.38, 1.25	0.2	
Season							
Cooldry	_	_		_	_		
Hotwet	0.82	0.55, 1.23	0.3	0.78	0.52, 1.17	0.2	
Socioeconomic status ²							
Medium/high ses (> 3)	_	_		_	_		
Low ses (<= 3)	1.21	0.81, 1.80	0.4	1.19	0.78, 1.83	0.4	
		· · · · · · · · · · · · · · · · · · ·			*		

¹ OR = Odds Ratio, CI = Confidence Interval

² Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Middle and high SES were combined

14515 5.1 45151	0 4000014104 1111	h pneumo		3 41 4111 19	,	
		Univariat	е		Multivarial	ble
Characteristic	OR^1	95% CI ¹	p-value	OR^1	95% CI ¹	p-value
HIV status						
HIV-	_	_		_	_	
PLHIV	2.24	1.22, 4.13	0.010	2.44	1.04, 5.69	0.039
Sex						
Female	_	_		_	_	
Male	0.89	0.52, 1.52	0.7	1.24	0.61, 2.53	0.6
Age group						
18-25	_	_		_	_	
26-35	1.85	0.90, 3.80	0.093	1.62	0.64, 4.13	0.3
36-45	2.13	1.01, 4.46	0.046	2.01	0.76, 5.34	0.2
Pernasal swab carriage density (CFU/mlj)					
Low density <=2010	_	_		_	_	
Medium/High density >2010	3.42	1.75, 6.67	<0.001	3.37	1.56, 7.29	0.002
Season						
Cooldry	_	_		_	_	
Hotwet	1.42	0.83, 2.43	0.2	1.18	0.58, 2.39	0.6
Socioeconomic status ²						
Medium/high ses (> 3)	_	_		_	_	
Low ses (<= 3)	0.59	0.34, 1.00	0.052	0.64	0.31, 1.31	0.2

¹ OR = Odds Ratio, CI = Confidence Interval

² Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Middle and high SES were combined

^{*} Pneumococcal shedding was defined as presence of viable pneumococci following microbiological culture of samples collected through nose poking (mechanical) and coughing or facemask sampling (aerosol).

Table 4. Baseline	pneumococcal c	arriage isolates a	ntibiogram
Characteristic	HIV- , $N = 35^1$	PLHIV , N = 57 ¹	p-value ²
Cotrimoxazole			0.002
Susceptible	8 (24%)	1 (2.0%)	
non-susceptible	26 (76%)	50 (98%)	
Oxacillin			0.5
Susceptible	15 (43%)	26 (51%)	
non-susceptible	20 (57%)	25 (49%)	
Tetracycline			0.2
Susceptible	16 (47%)	32 (63%)	
non-susceptible	18 (53%)	19 (37%)	
Erythromycin			0.058
Susceptible	21 (62%)	41 (80%)	
non-susceptible	13 (38%)	10 (20%)	
MDR ³			0.5
non MDR	26 (76%)	42 (82%)	
MDR ³	8 (24%)	9 (18%)	
¹ n (%)			

² Fisher's exact test; Pearson's Chi-squared test

 $^{^{3}}$ i.e. Oxacillin is excluded from MDR definition

Table 5. Pneumococcal shedding isolates antibiogram among PLHIV

	Aerosol shedding vs Nasopharyngeal carriage			Mechanical shedding vs Nasopharyngeal carriage			
Characteristic	Aerosol shedding, $N = 44^{7}$	Nasopharyngeal carriage, $N = 44^{7}$	p- value ²	Mechanical shedding, N = 50 ¹	Nasopharyngeal carriage, $N = 50^{1}$	p- value	
Tetracycline	27 (61%)	11 (26%)	<0.001	16 (32%)	15 (30%)	0.8	
Erythromycin	19 (43%)	12 (28%)	0.14	14 (28%)	16 (32%)	0.7	
Cotrimoxazole	41 (93%)	41 (95%)	>0.9	47 (94%)	46 (92%)	>0.9	
Benzylpenicillin ³	27 (61%)	14 (32%)	0.010	19 (38%)	14 (28%)	0.4	
MDR	28 (64%)	13 (30%)	0.001	15 (30%)	15 (30%)	>0.9	

 $^{^2\,\}mbox{Pearson's Chi-squared test; Fisher's exact test}$

³ i.e. Minimum inhibitory concentration